Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 100-107

  Truong, M ^a   Yang, B ^a   Wagner, J ^a   Kobayashi, Y ^b   Rajamanickam, V ^c   Brooks, J ^b,c   Jarrard, D F ^a  

^a University of Wisconsin Health   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

EVX1; methylation; prognosis; prostate cancer; PSA

Indexed keywords

AZACITIDINE; PROSTATE SPECIFIC ANTIGEN; TRICHOSTATIN A;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG TREATMENT FAILURE; EPIGENETICS; EVEN SKIPPED HOMEOBOX 1 GENE; EXON; GENE EXPRESSION REGULATION; GENE INDUCTION; HISTOPATHOLOGY; HOMEOBOX; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL;

AZACITIDINE; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA METHYLATION; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 84862994365     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.216     Document Type: Article

References (43)

1. Aitchison A, Warren A, Neal D, Rabbitts P (2007) RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67(6): 638-644 (Pubitemid 46685284)
2. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46(6): 698-708 (Pubitemid 39488398)
3. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11(10): 726-734
4. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF (2011) Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 71(15): 1621-1630
5. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T (2005) BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21(21): 4067-4068 (Pubitemid 41631851)
6. Briata P, Van De Werken R, Airoldi I, Ilengo C, Di Blas E, Boncinelli E, Corte G (1995) Transcriptional repression by the human homeobox protein EVX1 in transfected mammalian cells. J Biol Chem 270(46): 27695-27701
7. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7(4): 962-970 (Pubitemid 32708735)
8. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1): 103-107 (Pubitemid 29036293)
9. Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F, Teixeira MR, Jerónimo C (2010) Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 5(4): 343-351
10. Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, Meyer LR, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, Pohl A, Malladi VS, Li CH, Learned K, Kirkup V, Hsu F, Harte RA, Guruvadoo L, Goldman M, Giardine BM, Fujita PA, Diekhans M, Cline MS, Clawson H, Barber GP, Haussler D, James Kent W (2011) The UCSC Genome Browser database: extensions and updates 2011. Nucleic Acids Res 40(D1): D918-D923
11. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28(8): E32
12. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P (2002) Prognostic value of the Gleason score in prostate cancer. BJU Int 89(6): 538-542 (Pubitemid 34948295)
13. Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, von Ruecker A, Bastian PJ (2008) CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1): 42-49
14. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R (2004) CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64(17): 5956-5962 (Pubitemid 39129391)
15. Faiella A, D'Esposito M, Rambaldi M, Acampora D, Balsofiore S, Stornaiuolo A, Mallamaci A, Migliaccio E, Gulisano M, Simeone A (1991) Isolation and mapping of EVX1, a human homeobox gene homologous to even-skipped, localized at the 50 end of HOX1 locus on chromosome 7. Nucleic Acids Res 19(23): 6541-6545 (Pubitemid 21913087)
16. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196(2): 261-282 (Pubitemid 17122132)
17. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG (2006) Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 98(4): 255-261 (Pubitemid 43264709)
18. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW (2009) DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 15(1): 315-323
19. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C (2006) Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) 84(11): 911-918 (Pubitemid 44655869)
20. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17(3): 292-306 (Pubitemid 41646608)
21. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60(4): 753-766
22. Jones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293(5532): 1068-1070 (Pubitemid 32758075)
23. Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5): 1499-1507 (Pubitemid 29220858)
24. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R (2007) Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13(9): 2541-2548 (Pubitemid 46788019)
25. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21(7): 1017-1027
26. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B (2010) DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 90(7): 1060-1067
27. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE (2004) Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90(2): 535-541 (Pubitemid 38258278)
28. Li LC, Carroll PR, Dahiya R (2005) Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97(2): 103-115 (Pubitemid 40277090)
29. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18(11): 1427-1431 (Pubitemid 35414532)
30. Liu W, Gong J, Hu J, Hu T, Sun Y, Du J, Sun C, Guan M, Jiang H, Lu Y (2011) Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score. Urology 77(41006): e1-e7
31. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8(2): 514-519 (Pubitemid 34193971)
32. Mitsui Y, Shiina H, Hiraki M, Arichi N, Hiraoka T, Sumura M, Honda S, Yasumoto H, Igawa M (2012) Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer-novel predictor of biochemical recurrence after radical surgery. Cancer Epidemiol Biomarkers Prev 21(3): 487-496
33. Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Epigenetic alterations in human prostate cancers. Endocrinology 150(9): 3991-4002
34. Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB (2006) Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 4(2): 113-123
35. Rosenbaum E, Begum S, Brait M, Zahurak M, Maldonado L, Mangold LA, Eisenberger MA, Epstein JI, Partin AW, Sidransky D, Hoque MO (2011) AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate; e-pub ahead of print 29 November 2011; doi:10.1002/pros.22461
36. Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu H, Hsieh JT, Frenkel EP, Gazdar AF (2003) Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 9(17): 6395-6400 (Pubitemid 38031825)
37. Schulz WA, Hoffmann MJ (2009) Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19(3): 172-180
38. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF (2001) Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20(57): 8184-8192 (Pubitemid 34038207)
39. Spyropoulos DD, Capecchi MR (1994) Targeted disruption of the evenskipped gene, evx1, causes early postimplantation lethality of the mouse conceptus. Genes Dev 8(16): 1949-1961 (Pubitemid 24273894)
40. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA (2009) Gleason score and lethal prostate cancer: does 3+44+3? J Clin Oncol 27(21): 3459-3464
41. Sun W, Zaboli D, Wang H, Liu Y, Arnaoutakis D, Khan T, Khan Z, Koch WM, Califano JA (2012) Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res 18(4): 1082-1091
42. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C (2011) Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res 17(13): 4531-4540
43. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64(6): 1975-1986 (Pubitemid 38339443)